Radiologist performance has improved since the introduction of DBT for breast cancer screening

As the use of digital breast tomosynthesis (DBT) has markedly increased in recent years, so too have radiologists’ interpretive performances. 

A new paper published in Radiology compares radiologist performance when reading 2D and 3D mammography screenings. Based on more than 2 million screening exams included in the retrospective analysis and multiple measures, experts concluded that radiologists’ performance has significantly improved with the growing use of DBT. 

“Our study demonstrated that more radiologists in U.S. community practice are meeting recommended performance standards with digital breast tomosynthesis than they did with digital mammography,” said lead author Christoph I. Lee, MD, professor of radiology at the University of Washington (UW) School of Medicine in Seattle and director of the Northwest Screening and Cancer Outcomes Research Enterprise at UW. “This is good news for women and breast cancer screening, as digital breast tomosynthesis has quickly become the most popular breast cancer screening modality in the U.S.” 

Since receiving approval from the U.S. Food and Drug Administration in 2011, DBT has become the most common method for breast cancer screening and as of September 2022, 84% of all U.S. mammography screening facilities housed DBT units. 

Experts sought to assess whether the growing popularity of DBT screening has had any impact on radiologist performance benchmarks established by the Breast Cancer Surveillance Consortium (BCSC). To do this, the team analyzed DBT screening exams from five BCSC registries that occurred between 2011 and 2018. Altogether, this resulted in a total of 2,301,766 screening exams—458,175 DBT and 1,843,591 2D digital mammograms. 

Radiologist performance measures were based on abnormal interpretation rate (AIR), cancer detection rate (CDR), sensitivity, specificity and false-negative rate (FNR). The team found that use of DBT resulted in improved performance in every category except sensitivity and FNR, which were both in line with 2D performance measures. 

Lee signaled optimism for how such improved performance also could positively impact screening outcomes in the future.  

The study abstract is available here

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.